

Gilead Sciences Ukraine EFPIA Report 2022

Date of publication: 30/06/2023

	Full Name <i>(Ar. 14.1.1)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Ar. 14.3)</i>	Country of Principal Practice	Principal Practice Address <i>(Ar. 14.3)</i>	Unique country identifier OPTIONAL <i>(Ar. 14.3)</i>	Donations and Grants to HCOs <i>(Ar. 14.3.3)</i>	Costs associated with the Events <i>(Sub-clause, 14.3.3)</i>			Fees for service and consultancy <i>(Ar. 14.3.2 14.3.3)</i>		TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
H C P S	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE-where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - <i>Ar.14.3.4</i>											
Number of Recipients in aggregate disclosure - <i>Ar.14.3.4</i>												
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Ar.14.3.4</i>												
H C O S	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	OTHER, NOT INCLUDED ABOVE-where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - <i>Ar.14.3.4</i>											
Number of Recipients in aggregate disclosure - <i>Ar.14.3.4</i>												
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Ar.14.3.4</i>												
R & D	AGGREGATE DISCLOSURE											
	Transfers of Value re Research & Development as defined - Article 14.3.6											11,227,134.09 €